Reconsidering some approved antimicrobial agents for tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4577-4579

  Young, Lowell S ^a  

^a Kuzell Institute for Arthritis and Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CLAVULANIC ACID; COTRIMOXAZOLE; FOLIC ACID ANTAGONIST; IMIPENEM; ISONIAZID; LINEZOLID; MEFLOQUINE; MEROPENEM; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; TRIMETREXATE;

ANAEROBIC GROWTH; ANTIMICROBIAL THERAPY; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; HUMAN; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUBERCULOSIS;

EID: 70350329241     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00887-09     Document Type: Note

References (16)

1. Bermudez, L. E., P. Kolonoski, M. Wu, P. A. Aralar, C. B. Inderlied, and L. S. Young. 1999. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob. Agents Chemother. 43:1870-1874.
2. Chambers, H. F., T. Kocagoz, T. Sipit, J. Turner, and P. C. Hopewell. 1998. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26:874-877.
3. Chambers, H. F., J. Turner, G. F. Schecter, M. Kawamura, and P. C. Hopewell. 2005. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 49:2816-2821.
4. Cynamon, M. H., and G. S. Palmer. 1983. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 24:429-431.
5. Danelishvili, L., M. Wu, L. S. Young, and L. E. Bermudez. 2005. Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria. Antimicrob. Agents Chemother. 49:3707-3714.
6. Diacon, A. H., A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, L. Page-Shipp, C. Pistorius, R. Krause, M. Bogoshi, G. Churchyard, A. Venter, J. Allen, J. C. Palomino, T. De Marez, R. P. van Heeswijk, N. Lounis, P. Meyvisch, J. Verbeeck, W. Parys, K. de Beule, K. Andries, and D. F. McNeeley. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405.
7. Donald, P. R., and P. D. van Helden. 2009. The global burden of tuberculosis - combating drug resistance in difficult times. N. Engl. J. Med. 360: 2393-2395.
8. Forgacs, P., N. L. Wengenack, L. Hall, S. K. Zimmerman, M. L. Silverman, and G. D. Roberts. 2009. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother. 53:4789-4793.
9. Hugonnet, J.-E., L. W. Tremblay, H. I. Boshoff, C. E. Barry III, and J. S. Blanchard. 2009. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323:1215-1218.
10. Lenaerts, A. J., L. K. Woolhiser, V. Gruppo, I. M. Orme, R. C. Goldman, and C. Lambros. 2009. Mefloquine, moxifloxacin and pyrazinamide is a triple-drug alternative to isoniazid- and rifampin-containing regimens for treatment of tuberculosis in mice, abstr. B-1873. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
11. Makarov, V., G. Manina, K. Mikusova, U. Mollmann, O. Ryabova, B. Saint-Joanis, N. Dhar, M. R. Pasca, S. Buroni, A. P. Lucarelli, A. Milano, E. De Rossi, M. Belanova, A. Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J. D. McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I. Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, R. K. Shandil, V. Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, and S. T. Cole. 2009. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324:801-804.
12. Nannini, E. C., M. Keating, P. Binstock, G. Samonis, and D. P. Kontoyiannis. 2002. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J. Infect. 44:201-203. (Pubitemid 36104778)
13. Nikonenko, B. V., V. M. Reddy, M. Protopopova, E. Bogatcheva, L. Einck, and C. A. Nacy. 2009. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob. Agents Chemother. 53:3138-3139.
14. Rosowsky, A., R. A. Forsch., C. H. Sibley, C. B. Inderlied, and S. F. Queener. 2004. New 2,4-diamino-5-(2′,5′-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity. J. Med. Chem. 47:1475-1486.
15. van den Boogaard, J., G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse. 2009. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother. 53:849-862.
16. Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.